Skip to content
Sulfadiazine
Neotrizine, Sulfonamides Duplex (sulfadiazine) is a small molecule pharmaceutical. Sulfadiazine was first approved as Sulfadiazine on 1982-01-01. It is used to treat aids-related opportunistic infections, bacterial infections, chancroid, enterobacteriaceae infections, and malaria amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
otorhinolaryngologic diseasesD010038
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulfadiazine
Tradename
Company
Number
Date
Products
SULFADIAZINEAbbVieN-004125 DISCN1982-01-01
1 products
SULFADIAZINELederle LaboratoriesN-004054 DISCN1982-01-01
1 products
SULFADIAZINEEli LillyN-004122 DISCN1982-01-01
1 products, RLD
Hide discontinued
Sulfadiazine
+
Sulfamerazine
Tradename
Company
Number
Date
Products
SULFONAMIDES DUPLEXEli LillyN-006317 DISCN1982-01-01
1 products
Hide discontinued
Sulfadiazine sodium
Tradename
Company
Number
Date
Products
SULFADIAZINE SODIUMLederle LaboratoriesN-004054 DISCN1982-01-01
1 products
Hide discontinued
Sulfamerazine
+
Sulfamethazine)
+
Trisulfapyrimidines (sulfadiazine
Tradename
Company
Number
Date
Products
NEOTRIZINEEli LillyN-006317 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
silver sulfadiazineNew Drug Application2023-06-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aids-related opportunistic infections—D017088—
bacterial infections—D001424A49
chancroid—D002602A57
enterobacteriaceae infectionsEFO_1001313D004756—
malariaEFO_0001068D008288B54
meningococcal meningitisEFO_1001040D008585A39.0
nocardia infectionsEFO_0007397D009617A43
otitis mediaEFO_0004992D010033H66.9
toxoplasmosisEFO_0007517D014123B58
trachoma—D014141A71
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BA: Sulfonamides, topical
— D06BA01: Silver sulfadiazine
— D06BA51: Silver sulfadiazine, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01E: Sulfonamides and trimethoprim antibacterials for systemic use
— J01EC: Intermediate-acting sulfonamides
— J01EC02: Sulfadiazine
— J01EE: Combinations of sulfonamides and trimethoprim, incl. derivatives
— J01EE02: Sulfadiazine and trimethoprim
— J01EE06: Sulfadiazine and tetroxoprim
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSULFADIAZINE
INNsulfadiazine sodium
Description
Sulfadiazine is a sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position. It has a role as an antimicrobial agent, an antiinfective agent, a coccidiostat, an antiprotozoal drug, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor, an EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of pyrimidines, a sulfonamide, a substituted aniline and a sulfonamide antibiotic. It is functionally related to a sulfanilamide. It is a conjugate acid of a sulfadiazinate.
Classification
Small molecule
Drug classantimicrobials (sulfonamides derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
Identifiers
PDB—
CAS-ID68-35-9
RxCUI10171
ChEMBL IDCHEMBL439
ChEBI ID9328
PubChem CID5215
DrugBankDB00359
UNII ID84CS1P306F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 10,433 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details